Recent advances in β-thalassemias

Pediatric Reports

Volumn 3, Issue 2, 2011, Pages

  Cao, Antonio ^a   Moi, Paolo ^a   Galanello, Renzo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLOBULIN; BETA GLOBULIN; BUSULFAN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; GLOBIN; HEMOGLOBIN F; IMMUNOGLOBULIN; IRON CHELATING AGENT; LENTIVIRUS VECTOR; RETROVIRUS VECTOR;

ABDOMINAL PAIN; AGRANULOCYTOSIS; B CELL LYMPHOMA LEUKEMIA 11A GENE; BETA THALASSEMIA; CHROMOSOME 2; CHROMOSOME 6Q; CHROMOSOME IDENTIFICATION; DIARRHEA; DNA MODIFICATION; DOWN REGULATION; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC EPISTASIS; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOME ANALYSIS; HEART HEMOSIDEROSIS; HUMAN; IRON OVERLOAD; KRUEPPEL LIKE FACTOR1 GENE; MOLECULAR PATHOLOGY; MONOTHERAPY; MUTATIONAL ANALYSIS; NAUSEA; NON INVASIVE PROCEDURE; NONHUMAN; ONCOGENE; PROMOTER REGION; QUANTITATIVE TRAIT LOCUS; RASH; RECOMMENDED DRUG DOSE; REGULATOR GENE; REVIEW; SICKLE CELL ANEMIA; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL TRANSPLANTATION; THALASSEMIA; THALASSEMIA MAJOR; UPREGULATION; VIRAL GENE THERAPY; VOMITING;

EID: 83155167192     PISSN: None     EISSN: 20367503     Source Type: Journal    
DOI: 10.4081/pr.2011.e17     Document Type: Review

References (156)

1. Wheatherall DJ, Clegg JB. The Thalassemia Syndromes. 4th Ed. 2001 Blackwell Science Ltd.
2. Cao A, Galanello R. Beta-Thalassemia. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2000 [updated 2010].
3. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001;2:245-55.
4. Thein SL. Genetic modifiers of the betahaemoglobinopathies. Br J Haematol 2008;141:357-66.
5. Cao A, Galanello R, Rosatelli MC. Genotype-phenotype correlations in betathalassemias. Blood Rev 1994;8:1-12.
6. Thein SL. Genetic modifiers of beta-thalassemia. Haematologica 2005;90:649-60.
7. Stamatoyannopoulos G. Molecular an cellular basis of haemoglobin switching. In Steinberg, MH., Forget, B.G., Higgs, D.R. and Nagel, R.L. (eds) Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinica Management. Cambridge University Press, Cambridge UK, pp 131-145.
8. Boyer SH, Belding TK, Margolet L, Noyes AN. Fetal hemoglobin restriction to a few erythrocytes (F cells) in normal human adults. Science 1975;188:361-3.
9. Garner C, Tatu T, Reittie JE, et al. Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood 2000;95:342-6.
10. Gilman JG, Huisman TH. DNA sequence variation associated with elevated fetal G gamma globin production. Blood 1985;66:783-7.
11. Garner C, Tatu T, Game L, et al. A candidate gene study if F cell levels in sibling pairs using a joint linkage and association analysis. Gene Screen 2000;1:9-14.
12. Labie D, Dunda-Belkhodja O, Rouabhi F, et al. The -158 site 5' to the G gamma gene and G gamma expression. Blood 1985;66:1463-5.
13. Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci U S A 2007;104:11346-51.
14. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A 2008;105:1620-5.
15. Galarneau G, Palmer CD, Sankaran VG, et al. Fine-mapping at three loci known to effect fetal hemoglobin levels explains additional genetic variation. Nat Genetics 2010;42:1049-51.
16. Thein SL, Weatherall DJ. A non-deletion hereditary persistence of fetal hemoglobin (HPFH) determinant not linked to the beta-globin gene complex. Prog Clin Biol Res 1989;316B:97-111.
17. Thein SL, Sampietro M, Rohde K, et al. Detection of a major gene for heterocellular hereditary persistence of fetal hemoglobin after accounting for genetic modifiers. Am J Hum Genet 1994;54:214-28.
18. Wahlberg K, Jiang J, Rooks H, et al. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood 2009;114:1254-62.
19. Sankaran VG, Menne TF, Scepanovic D, et al. MicroRNA-15° and -16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci U S A 2011 Jan 4. [Epub ahead of print]
20. Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. Hum Mol Genet 2009;18: R216-23.
21. Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A 2008;105:11869-74.
22. Galanello R, Sanna S, Perseu L, et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood 2009;114:3935-7.
23. Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007;39: 1197-9.
24. Sedgewick AE, Timofeev N, Sebastiani P, et al. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. Blood Cells Mol Dis 2008;41:255-8.
25. Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood 2010;115:1815-22.
26. Dover GJ, Smith KD, Chang YC, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992;80:816-24.
27. Miyoshi K, Kaneto Y, Kawai H, et al. Xlinked dominant control of F-cells in normal adult life: characterization of the Swiss type as hereditary persistence of fetal hemoglobin regulated dominantly by gene(s) on X chromosome. Blood 1988;72:1854-60.
28. Garner C, Silver N, Best S, et al. Quantitative trait locus on chromosome 8q influences the switch from fetal to adult hemoglobin. Blood 2004;104:2184-6.
29. Wilber A, Hargrove PW, Kim YS, et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of {beta}-thalassemic CD34+ cells following lentiviral vectormediated gene transfer Blood 2010 Dec 14. [Epub ahead of print]
30. Liu P, Keller JR, Ortiz M, et al. Bcl11a is essential for normal lymphoid development. Nat Immunol 2003;4:525-32.
31. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008;322:1839-42.
32. Bank A. Regulation of human fetal hemoglobin: new players, new complexities. Blood 2006;107:435-43.
33. Sankaran VG, Xu J, Orkin SH. Advances in the understanding of haemoglobin switching. Br J Haematol 2010;149:181-94.
34. Jawaid K, Wahlberg K, Thein SL, Best S. Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus. Blood Cells Mol Dis 2010;45:140-6.
35. Feingold EA, Forget BG. The breakpoint of a large deletion causing hereditary persistence of fetal hemoglobin occurs within an erythroid DNA domain remote from the beta-globin gene cluster. Blood 1989;74:2178-86.
36. Chen Z, Luo HY, Steinberg MH, Chui DH. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis 2009;42: 144-9.
37. Xu J, Sankaran VG, Ni M, et al. Transcriptional silencing of {gamma}-globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev 2010;24:783-98.
38. Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009;460:1093-7.
39. Bieker JJ. Probing the onset and regulation of erythroid cell-specific gene expression.Mt Sinai J Med 2005;72:333-8.
40. Perkins AC, Sharpe AH, Orkin SH. Lethal β-Thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature 1995;375:318-322.
41. Nuez B, Michalovic D, Bygrave A, et al. Defective haematopoiesis in fetal liver resulting from inactivation the EKLF gene. Nature 1995;375:316-318.
42. Moi P, Faà V, Marini MG, et al. A novel silent beta-thalassemia mutation in the distal CACCC box affects the binding and responsiveness to EKLF. Br J Haematol 2004;126:881-4.
43. Zhou D, Liu K, Sun CW, et al. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat Genet 2010;42:742-4.
44. Borg J, Papadopoulos P, Georgitsi M, et al. Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin. Nat Genet 2010;42:801-5.
45. Singleton BK, et al. A novel EKLF mutation in a patient with dyserythropoietic anemia: the first association of EKLF with disease in man. Blood 2009;114:A162.
46. Siatecka M, Sahr KE, Andersen SG, et al. Severe anemia in the Nan mutant mouse caused by sequence-selective disruption of erythroid Kruppel-like factor. Proc Natl Acad Sci U S A 2010;107:15151-6.
47. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematol 2004;89:1187-93.
48. Restivo Pantalone G, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Haematol 2010;150:245-7.
49. Telfer PT, Warburton F, Christou S, et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematol 2009;94:1777-8.
50. Modell B, Khan M, Darlison M, et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008;10:42.
51. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107:3738-44.
52. Tanner MA, Galanello R, Dessi C, et al. A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance. Circulation 2007; 115:1876-84.
53. Angelucci E, Baronciani D, Lucarelli G, et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995;89:757-61.
54. Ambu R, Crisponi G, Sciot R, et al. Uneven hepatic iron and phosphorus distribution in beta-thalassemia. J Hepatol 1995;23:544-9.
55. Emond MJ, Bronner MP, Carlson TH, et al. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999;45:340-6.
56. Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003;121:938-48.
57. Westwood MA, Firmin DN, Gildo M, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 2005;21:531-8.
58. Tanner MA, He T, Westwood MA, et al. Multi-center validation of the transferability of the magnetic resonance T2* technique for the quantification of tissue iron. Haematol 2006;91:1388-91.
59. Ghugre NR, Coates TD, Nelson MD, Wood JC. Mechanisms of tissue-iron relaxivity: nuclear magnetic resonance studies of human liver biopsy specimens. Magn Reson Med 2005;54:1185-93.
60. Wood JC, Fassler JD, Meade T. Mimicking liver iron overload using liposomal ferritin preparations. Magn Reson Med 2004;51:607-11.
61. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9.
62. Kirk P, Smith GC, Roughton M, et al. Myocardial T2* is not affected by ageing, myocardial fibrosis, or impaired left ventricular function. J Magn Reson Imaging 2010;32:1095-8.
63. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program 2009:215-21.
64. St Pierre TG, Clark PR, Chua-Anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-61.
65. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005;106:1460-5.
66. Vogiatzi MG, Macklin EA, Trachtenberg FL, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America. Br J Haematol 2009;146:546-56.
67. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010;116:537-43.
68. Au WY, Lam WW, Chu W, et al. A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major. Haematol 2008;93:116-9.
69. Noetzli LJ, Papudesi J, Coates TD, Wood JC. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009;114:4021-6.
70. Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV. 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;1:1294-5.
71. Hoffbrand AV. Oral iron chelators in the treatment of hematologic diseases. Clin Adv Hematol Oncol 2005;3:536-8.
72. Matsui D, Klein J, Hermann C, et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991;50:294-8.
73. Al-Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995;89:403-8.
74. Collins AF, Fassos FF, Stobie S, et al. Ironbalance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994; 83:2329-33.
75. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102:17-24.
76. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-9.
77. Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002;28:196-208.
78. Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. The Lancet 2002;360:516-20.
79. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematol 2003;88:489-96.
80. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006;107:3733-7.
81. Hider RC, Liu ZD. Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overload. Curr Med Chem 2003;10:1051-64.
82. Wu KH, Chang JS, Tsai CH, Peng CT. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with betathalassemia major. Ann Hematol 2004;83:471-3.
83. Porcu M, Landis N, Salis S, et al. Effects of combined deferiprone and desferrioxamine iron chelating therapy in beta-thalassemia major end-stage heart failure A case report. Europ J Heart Fail 2007;9: 320-2.
84. Fabio G, Minonzio F, Delbini P, et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007;109:362-4.
85. Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008;10:12.
86. Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148:466-75.
87. Telfer P, Coen PG, Christou S, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. Haematol 2006;91:1187-92.
88. Galanello R, Kattamis CA, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematol 2006;91: 1241-3.
89. Maggio A, Vitrano A, Capra M, et al. Longterm sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 2009;145:245-54.
90. Maggio A, Vitrano A, Capra M, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Blood Cells Mol Dis 2009;42:247-51.
91. Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003;102:1583-7.
92. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002;118:330-6.
93. El Alfy M, Sari TT, Lee CL, et al. The safety, tolerability,and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol 2010;32:601-5.
94. Choudhry VP, Pati HP, Saxena A, Malaviya AN. Deferiprone, efficacy and safety. Indian J Pediatr 2004;71:213-6.
95. Porter JB. Optimizing iron chelation strategies in beta-thalassaemia major. Blood Rev 2009;23 Suppl 1:S3-S7.
96. Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000;108:305-12.
97. Apotex Research: Ferriprox pediodic safety update report, PSUR, Toronto, Apotex, 2003
98. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 2003;10:1065-76.
99. Galanello R, Piga A, Alberti D, et al. Safety, Tolerability, and Pharmacokinetics of ICL670, a New Orally Active Iron-Chelating Agent in Patients with Transfusion-Dependent Iron Overload Due to ~́-Thalassemia. J Clin Pharmacol 2003; 43:565-72.
100. Nisbet-Brown E, Olivieri NF, Giardina PJ,et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-602.
101. Porter JB, Vichinsky E, Rose C, et al. A phase II study with ICL670 (Exjade), a once-daily oral iron chelator, in patients with various transfusio-dependent anemias and iron overload. Blood 2004; 104:872A.
102. Vichinsky E, Fischer R, Fung E, et al. A randomized, controlled phase II trial in sickle cell disease patients with chronic iron overload demontrates that the oncedaily oral iron chelator deferasirox (Exjade ICL670) is well tolerated and reduces iron. Blood 2005;106:95°.
103. Piga A, Galanello R, Cappellini MO, et al. Phase II study of ICL670, an oral chelator, in adult thalassemia patients with trasfusional iron overload: Efficacy, safety, pharmaco kinetics (PK) and pharmacodyamics (PD) after 18 months of therapy. Blood 2003;102:121A.
104. Piga A, Galanello R, Foschini L, et al. Once-daily treatment with the oral iron chelator ICL670(Exjade): Results of a phase II study in pediatric patients with beta thalassemia major. Blood 2004;104:983A.
105. Cappellini MD, Cohen AR, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-62.
106. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009;82:454-7.
107. Ladis V, Berdousi H, Gotsis E, Kattamis A. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Br J Haematol 2010;151:504-8
108. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade©, ICL670), a once-daily, orallyadministered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematol 2006;91:873-80.
109. Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009;82:458-65.
110. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009;147:752-9.
111. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematol 2010;95:557-66.
112. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematol 2006;91:1343-51.
113. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008;111:583-7.
114. Piga A, Kebaili K, Galanello R. Cumulative efficacy and safety of 5-year deferasirox (Exjade) treatment in pediatric patients with thalassemia major: a phase II multicenter prospective trial. Blood 2008;112:5413A.
115. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in betathalassemia. Blood 2010;115:2364-71.
116. Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematol 2011;96:48-54.
117. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol 2008;119:133-41.
118. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther 2007;29:909-17.
119. Taher A, Al Jefri A, Elalfy MS, et al. Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol 2010;123:220-5.
120. Galanello R, Agus A, Campus S, et al. Combined iron chelation therapy. Ann N Y Acad Sci 2010;1202:79-86.
121. Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. J Pediatr Hematol Oncol 2010;32:400-3.
122. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Am J Hematol2010; 85:460-1.
123. Porter JB. Deferasirox--current knowledge and future challenges. Ann N Y Acad Sci 2010;1202:87-93.
124. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008;83:398-402.
125. Porter JB. Deferasirox: an update. Hemoglobin 2009;33:S70-5.
126. Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 2010;32:564-7.
127. Rheault MN, Bechtel H, Neglia JP, Kashtan CE. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer 2010 Dec. [Epub ahead of print]
128. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005;1054:40-7.
129. Cao A. Quality of life and survival of patients with beta-thalassemia major. Haematol 2004;89: 1157-9.
130. Lai ME, Grady RW, Vacquer S, et al. Increased survival and reversion of ironinduced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis 2010;45:136-9.
131. La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci 2005; 1054:186-95.
132. Isgro A, Marziali M, Sodani P, et al. Immunohematologic reconstitution in pediatric patients after T cell-depleted HLA-haploidentical stem cell transplantation for thalassemia. Biol Blood Marrow Transplant 2010;16:1557-66.
133. Moi P, Sadelain M. Towards the genetic treatment of beta-thalassemia: new disease models, new vectors, new cells. Haematol 2008;93:325-30.
134. Case SS, Price MA, Jordan CT, et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci U S A 1999;96:2988-93.
135. Tisdale J, Sadelain M. Toward gene therapy for disorders of globin synthesis. Semin Hematol 2001;38:382-92.
136. May C, Sadelain M. A promising genetic approach to the treatment of beta-thalassemia. Trends Cardiovasc Med 2001;11:276-80.
137. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001;294:2368-71.
138. Rivella S, May C, Chadburn A, et al. M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003;101:2932-9.
139. Puthenveetil G, Scholes J, Carbonell D, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004;104:3445-53.
140. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A 1996;93:11382-8.
141. Dull T, Zufferey R, Kelly M, et al. A thirdgeneration lentivirus vector with a conditional packaging system. J Virol 1998;72: 8463-71.
142. Gelinas R, Novak U. Retroviral vectors for the beta-globin gene that demonstrate improved titer and expression. Ann N Y Acad Sci 1990;612:427-41.
143. Hanawa H, Hargrove PW, Kepes S, et al. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine beta-thalassemia. Blood 2004;104:2281-90.
144. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000;406:82-6.
145. Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A 2008;105:10547-52.
146. Lisowski L, Sadelain M. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. Blood 2007;110:4175-8.
147. Emery DW, Yannaki E, Tubb J, et al. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 2002;100:2012-9.
148. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010;467:318-22.
149. Italiano A, Bianchini L, Keslair F, et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 2008;122:2233-41.
150. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315:1576-9.
151. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30.
152. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.
153. Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-3
154. Papapetrou EP, Lee G, Malani N, et al. Genomic safe harbors permit high betaglobin transgene expression in thalassemia induced pluripotent stem cells. Nat Biotechnol 2011;29:73-8.
155. Si-Tayeb K, Noto FK, Sepac A, et al. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Biol 2010;10:81.
156. Sommer CA, Sommer AG, Longmire TA, et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 2010;28:64-74.